Latest News

Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

Comprehensive Viral Genotyping for Head and Neck Cancers.

Researchers developed a new tool aimed at better classifying HPV+ HNSCC patients with good or poor prognosis in an effort to personalize treatment and improve patient outcomes.

Oropharyngeal squamous cell carcinoma (OPSCC) accounts for over half of all head and neck cancers. Since the 1970s, OPSCC has shifted from an environmentally triggered to virally mediated disease due to a sharp rise in human papillomavirus (HPV)-related SCC.

Connecticut Magazine has named 87 Yale Cancer Center and Smilow Cancer Hospital physicians to its 2022 Best Doctors guide.

Head and neck squamous cell carcinoma (HNSCC) is a frequently devastating cancer that affects more than a half million people annually worldwide. In a paper recently published in AACR Journals, Dr. Barbara Burtness reveals the relation of the interaction of TP53 and CDKN2A mutations with elevated tumor mutation burden in HNSCC.

In recognition of Head and Neck Cancer Awareness Month, Manju Prasad, MD, MBBS, Professor of Pathology; Director, Endocrine Head and Neck Pathology Fellowship Program; Director, Endocrine Head and Neck Pathology, provides her insight.

Transoral robotic surgery followed by low-dose radiation may reduce treatment intensity and improve long-term quality of life compared to usual care, which consists of high-dose radiation and chemotherapy, in patients with HPV-associated throat cancer, recent study findings demonstrate.

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.